Ras redux: Rethinking how and where Ras acts

Current Opinion in Genetics and Development

Volumn 13, Issue 1, 2003, Pages 6-13

  Hingorani, Sunil R ^a   Tuveson, David A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; RAS PROTEIN;

CANCER THERAPY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0037310529     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(02)00017-5     Document Type: Review

References (58)

1. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl. Acad. Sci. U.S.A. 79:1982;3637-3640.
2. Parada L.F., Tabin C.J., Shih C., Weinberg R.A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 297:1982;474-478.
3. Santos E., Tronick S.R., Aaronson S.A., Pulciani S., Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature. 298:1982;343-347.
4. Bos J.L. The ras gene family and human carcinogenesis. Mutat. Res. 195:1988;255-271.
5. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
6. Chiu V.K., Bivona T., Hach A., Sajous J.B., Silletti J., Wiener H., Johnson R.L. II, Cox A.D., Philips M.R. Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 4:2002;343-350 Through the use of a fluorescence-tagged Ras-binding domain reporter, the authors demonstrate that Ras can engage and activate effector signaling pathways from endomembrane compartments to induce biological outcomes. These findings subvert previous dogma restricting Ras activity to the PM. Together with other studies demonstrating distinct subcellular compartmentalization of Ras isoforms, these data may also explain how Ras proteins induce isoform-specific cellular responses.
7. Lazarov M., Kubo Y., Cai T., Dajee M., Tarutani M., Lin Q., Fang M., Tao S., Green C.L., Khavari P.A. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat. Med. 8:2002;1105-1114 On the basis of evidence for a new link between ras overexpression and down-regulation of CDK4 protein levels, the authors present a unique model for transforming human keratinocytes requiring ectopic coexpression of ras and CDK4 only. Ras/CDK4 co-transduced keratinocytes form invasive tumors resembling SCC in xenograft models. Curiously, however, such cells are neither immortal nor transformed by standard tissue culture criteria. This model may prove useful not only for exploring the minimal requirements to make human tumor cells but also to investigate the dynamic reciprocal interactions between tumor cells and tissue microenvironment and the efficacy of potential targeted therapies against Ras and CDKs.
8. Hamad N.M., Elconin J.H., Karnoub A.E., Bai W., Rich J.N., Abraham R.T., Der C.J., Counter C.M. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16:2002;2045-2057 The authors express effector-specific ras mutants in different human cell types immortalized with hTERT and SV40 large T and small t antigens to determine which pathway(s) is predominant in causing transformation. Surprisingly, and in contrast to a large body of evidence in rodent systems, activation of the RalGEF pathway alone is sufficient to cause these permissive human cells to grow in soft agar. Neither PI3K-specific nor MAPK-specific mutants, either alone or in combination, could do so. Notably, however, activation of all three pathways was necessary for these cells to form tumors in nude mice. Nevertheless, these data require reassessment of the view that the MAPK pathway predominates in promoting proliferation and transformation, at least in human cells.
9. Cullen P.J. Ras effectors: buying shares in Ras plc. Curr. Biol. 11:2001;R342-R344.
10. Khokhlatchev A., Rabizadeh S., Xavier R., Nedwidek M., Chen T., Zhang X.F., Seed B., Avruch J. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12:2002;253-265.
11. Bos J.L. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. EMBO J. 17:1998;6776-6782.
12. Shields J.M., Pruitt K., McFall A., Shaub A., Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10:2000;147-154.
13. Bar-Sagi D. A Ras by any other name. Mol. Cell Biol. 21:2001;1441-1443.
14. Olson M.F., Marais R. Ras protein signalling. Semin. Immunol. 12:2000;63-73.
15. Katz M.E., McCormick F. Signal transduction from multiple Ras effectors. Curr. Opin. Genet. Dev. 7:1997;75-79.
16. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351:2000;289-305.
17. Bourne H.R., Sanders D.A., McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 348:1990;125-132.
18. Cichowski K., Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 104:2001;593-604.
19. Glomset J.A., Farnsworth C.C. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu. Rev. Cell Biol. 10:1994;181-205.
20. Magee T., Marshall C. New insights into the interaction of Ras with the plasma membrane. Cell. 98:1999;9-12.
21. Choy E., Chiu V.K., Silletti J., Feoktistov M., Morimoto T., Michaelson D., Ivanov I.E., Philips M.R. Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell. 98:1999;69-80.
22. Apolloni A., Prior I.A., Lindsay M., Parton R.G., Hancock J.F. H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol. Cell Biol. 20:2000;2475-2487.
23. Thissen J.A., Gross J.M., Subramanian K., Meyer T., Casey P.J. Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking. J. Biol. Chem. 272:1997;30362-30370.
24. Chen Z., Otto J.C., Bergo M.O., Young S.G., Casey P.J. The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules. J. Biol. Chem. 275:2000;41251-41257.
25. Roy S., Luetterforst R., Harding A., Apolloni A., Etheridge M., Stang E., Rolls B., Hancock J.F., Parton R.G. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat. Cell Biol. 1:1999;98-105.
26. Prior I.A., Harding A., Yan J., Sluimer J., Parton R.G., Hancock J.F. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat. Cell Biol. 3:2001;368-375 Together with their earlier study on the effects of disrupting calveolae [25], the authors demonstrate that H-ras and K-ras4B segregate to discrete domains within the inner leaflet of the PM and, in the case of H-ras, that this specific sublocalization is necessary for biological activity. In addition, for maximal efficacy, H-ras must be able to shift laterally in a GTP-dependent manner from lipid rafts into the disordered PM. The authors also establish a new function for the linker sequence of the hypervariable region, as its deletion prevents this release of H-ras from rafts. The existence of specialized islands of H-ras activity amidst a disordered lipid sea scattered with K-ras may contribute to the abilities of these isoforms to engender unique cellular responses.
27. Simons K., Ikonen E. Functional rafts in cell membranes. Nature. 387:1997;569-572.
28. Anderson R.G. The caveolae membrane system. Annu. Rev. Biochem. 67:1998;199-225.
29. Gibbs J.B., Graham S.L., Hartman G.D., Koblan K.S., Kohl N.E., Omer C.A., Oliff A. Farnesyltransferase inhibitors versus Ras inhibitors. Curr. Opin. Chem. Biol. 1:1997;197-203.
30. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:1995;179-185.
31. Rebollo A., Perez-Sala D., Martinez A.C. Bcl-2 differentially targets K-, N-, and H-Ras to mitochondria in IL-2 supplemented or deprived cells: implications in prevention of apoptosis. Oncogene. 18:1999;4930-4939.
32. Land H., Parada L.F., Weinberg R.A. Cellular oncogenes and multistep carcinogenesis. Science. 222:1983;771-778.
33. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:1997;593-602.
34. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
35. Ewen M.E., Oliver C.J., Sluss H.K., Miller S.J., Peeper D.S. p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. Genes Dev. 9:1995;204-217.
36. Ewen M.E., Sluss H.K., Whitehouse L.L., Livingston D.M. TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell. 74:1993;1009-1020.
37. Tremain R., Marko M., Kinnimulki V., Ueno H., Bottinger E., Glick A. Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene. 19:2000;1698-1709.
38. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
39. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer. 1:2001;222-231.
40. Sotillo R., Dubus P., Martin J., de la Cueva E., Ortega S., Malumbres M., Barbacid M. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20:2001;6637-6647.
41. Rane S.G., Cosenza S.C., Mettus R.V., Reddy E.P. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol. Cell Biol. 22:2002;644-656.
42. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta. 1602:2002;73-87.
43. -/- MEFs can be fully transformed by transduction with either ras or neu. These findings suggest that a subset of human cancers might be uniquely sensitive to disruption of cyclin D1 function.
44. White M.A., Nicolette C., Minden A., Polverino A., Van Aelst L., Karin M., Wigler M.H. Multiple Ras functions can contribute to mammalian cell transformation. Cell. 80:1995;533-541.
45. Voice J.K., Klemke R.L., Le A., Jackson J.H. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J. Biol. Chem. 274:1999;17164-17170.
46. Walsh A.B., Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J. Biol. Chem. 276:2001;15609-15615.
47. Yan J., Roy S., Apolloni A., Lane A., Hancock J.F. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. 273:1998;24052-24056.
48. Umanoff H., Edelmann W., Pellicer A., Kucherlapati R. The murine N-ras gene is not essential for growth and development. Proc. Natl. Acad. Sci. U.S.A. 92:1995;1709-1713.
49. Koera K., Nakamura K., Nakao K., Miyoshi J., Toyoshima K., Hatta T., Otani H., Aiba A., Katsuki M. K-ras is essential for the development of the mouse embryo. Oncogene. 15:1997;1151-1159.
50. Johnson L., Greenbaum D., Cichowski K., Mercer K., Murphy E., Schmitt E., Bronson R.T., Umanoff H., Edelmann W., Kucherlapati R.et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11:1997;2468-2481.
51. Bos J.L. Ras oncogenes in hematopoietic malignancies. Hematol. Pathol. 2:1988;55-63.
52. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clin. Cancer Res. 6:2000;2969-2972.
53. Onida F., Kantarjian H.M., Smith T.L., Ball G., Keating M.J., Estey E.H., Glassman A.B., Albitar M., Kwari M.I., Beran M. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 99:2002;840-849.
54. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature. 414:2001;105-111.
55. Joneson T., Bar-Sagi D. Suppression of Ras-induced apoptosis by the Rac GTPase. Mol. Cell Biol. 19:1999;5892-5901.
56. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410:2001;1111-1116.
57. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:2001;3243-3248.
58. Lopez I., Mak E.C., Ding J., Hamm H.E., Lomasney J.W. A novel bifunctional phospholipase c that is regulated by Galpha 12 and stimulates the Ras/mitogen-activated protein kinase pathway. J. Biol. Chem. 276:2001;2758-2765.